Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma × tislelizumab × Clear all
NCT05977673 2025-12-08

FIL_Tisle-HL

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT05477264 2024-04-03

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Samsung Medical Center

Phase 2 Recruiting
38 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡